Antibody Panel for Diagnosis and Prognosis of Cancer

Description:

Project ID: BIO00196

Novelty:

The invention comprises of an antibody-based panel for detecting the cadherin family of proteins, the catenin family of proteins and the plaque family of proteins in tissues for the diagnosis and prognosis of cancer.

Value proposition:

The present invention finds use in the assessment and differential diagnosis of tumors in tissue. The panel includes a set of antibody reagents; each antibody reagent is capable of recognizing a specific protein where the protein is a member of the general cadherin family of proteins, the general catenin family of proteins or the plaque family of proteins. The antibody-based panel includes one or more antibody reagents specific for detecting the cadherin family of proteins selected from the group consisting of E-cadherin, P-cadherin, N-cadherin, M-cadherin, R-cadherin, OB-cadherin, desmosomal cadherins and protocadherins and/or one or more antibody reagents specific for detecting the catenin family of proteins selected from the group consisting of α-catenin, β-catenin, plakoglobin, p120cas  isoforms and other plaque proteins, such as, vinculin, α-actinin, desmoplakin, plakophilin, and the like.

Invention description:

Adhesion between cells is a feature of all multicellular organisms, including humans. One class of proteins that mediate adhesion between cells is the cadherin family of proteins. The extracellular interactions between two cadherin molecules contribute to holding neighboring cells together. Also, on the inside surface of the cell membrane, the cytoplasmic domain of the cadherin protein interacts with a set of proteins called catenins or plaque proteins. One of the characteristic features of cancer cells is that, relative to their normal counterparts, their cell adhesion systems are different. One manifestation of their altered cell adhesion properties is that many cancers can become metastatic. Thus, it is of interest to determine the status of cell adhesion molecules in cancer cells.  A reduction in cadherin expression as well as functional alterations such as tyrosine phosphorylation, decrease cell-cell adhesion and are associated with tumor progression. Thus cadherins, and their associated proteins, the catenins, are used as prognostic indicators of tumor aggressiveness. It is believed that when present, cadherin expression in tumors may also be used to trace the histogenetic origins of the tumor cells, and serve as differential diagnosis markers between neoplasms of similar morphology but different histogenesis.

Researchers at The University of Toledo have invented a panel of antibodies for detecting cadherins, catenins or plaque proteins in tissues and have provided the method of use of this panel in the diagnosis and prognosis of human cancers.

Applications: Cancer diagnostics and prognosis

IP status: US Patent 5,895,748; US Patent 5,997,866

Patent Information:
Category(s):
Cancer
Research Tools
For Information, Contact:
Stephen Snider
AVP Tech Transfer
The University of Toledo
419 530 6225
Stephen.Snider@utoledo.edu
Inventors:
Keith Johnson
Margaret Wheelock
Alejandro Soler
Karen Knudsen
Keywords:
Cadherin
Cancer
Catenin
Diagnosis
Prognosis